Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA
Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA
In this 24-week, multi-center, randomized, double-blind study, the investigators will
 evaluate the efficacy and safety profile of subcutaneously injected Yisaipu, a Tumor Necrosis
 Factor Receptor Fusion Protein, combined with oral Tripterygium Wilfordii for patients with
 active rheumatoid arthritis.
This study evaluates the efficacy and safety of YISAIPU plus Tripterygium wilfordii (T2w) for
 the treatment of RA patients. YISAIPU is a recombinant human tumor necrosis factor receptor
 fusion protein, and tripterygium wilfordii is a chloroform/methanol extract of Tripterygium
 wilfordii Hook F.

 Objectives:

 1. To compare the efficacy of YISAIPU plus T2w versus MTX monotherapy for the treatment of
 signs and symptoms of RA.

 2. To evaluate the safety of YISAIPU plus T2w in patients with RA for 24 weeks.

 Design:

 This is a Phase 2, randomized, 24-week, double-blind, parallel group study, and 506 patients
 with active RA will be randomized in a 1:1:1:1 ratio to one of the following four parallel
 treatment arms:

 1. Methotrexate monotherapy

 2. T2w monotherapy

 3. YISAIPU plus methotrexate

 4. YISAIPU plus T2w

 Escape:

 On week 12, all participants with inadequate response, defined as a <30% improvement of
 swollen and tender joint counts from baseline, will switch to YISAIPU plus T2w treatment
 throughout the study.

 Endpoints :

 1. ACR20, ACR50 and ACR70 response rates at 4, 12 and 24 weeks.

 2. DAS 28 (CRP) and DAS 28 (ESR) at 4, 12 and 24 weeks.

 3. EULAR response rates at 4, 12 and 24 weeks.

 4. Health assessment questionnaire (HAQ) at 4, 12 and 24 weeks.

 5. Patient assessment of arthritis pain at 4, 12 and 24 weeks.

 6. Patient and physician global assessment of arthritis at 4, 12 and 24 weeks.
Inclusion Criteria:

 -  Age 18-65 years with informed consent

 -  Fulfill the 2010 ACR/EULAR classification criteria for rheumatoid arthritis

 -  Disease duration > 6 weeks

 -  Swollen joint (SJC)≥4 and tender joint count(TJC)≥4

 -  ESR >28 mm/hr or C-reactive protein > 1.5 ULN

 -  Positive RF or anti-CCP antibody on screening

 -  Class I, II or III of the ACR 1991 Revised Criteria for Global Functional Status in RA

 -  No evidence of active or latent or inadequately treated Mycobacterium tuberculosis
 infection

 Exclusion Criteria:

 -  Pregnant, lactating or further fertility requirements

 -  Previously received any biologic agents.

 -  Recently (<12 weeks) received methotrexate, leflunomide, salazosulfapyridine,
 azathioprine, cyclosporine, mycophenolate mofetil or Tripterygium Wilfordii.

 -  Active or chronic infection, including HIV, HCV, HBV, tuberculosis.

 -  History of any other rheumatic autoimmune disease

 -  History of any lymphoproliferative disorder

 -  Malignancy or history of malignancy.

 -  Abnormal laboratory tests, including: Hemoglobin <8.5 g/dL, White blood cell count
 <3.5 x 109/L, Platelet count <100 x 109/L, AST/ALT >1.5 ULN, and serum creatine > 1.5
 mg/dL.

 -  Severe, progressive, or uncontrolled cardiac, pulmonary, renal, hepatic,
 gastrointestinal, hematologic, metabolic, endocrine or neurologic disease